Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005947 · ClinicalTrials.gov registry record · Phase 3
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 3 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT00005947 is a Phase 3 study that has completed, run by Dendreon. The registered enrollment target is 127 participants.
The verdict
NCT00005947, a Phase 3 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer. Purpose: Randomized phase III trial to determine the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 1999-11 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005947
The ClinicalTrials.gov registry entry for NCT00005947 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00005947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005947 about?
NCT00005947 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer. Purpose: Randomized phase III trial to determine the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer...
What is the current status of trial NCT00005947?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 1999-11. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00005947?
The interventions under investigation include: Placebo (BIOLOGICAL), sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005947?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.